Mazindol
Aliases: Sanorex, Mazanor, Teronac, Terenac, Dimagrir
Summary
Mazindol is a tricyclic anorexigenic agent approved for short-term obesity treatment and off-label narcolepsy management. Unlike amphetamines, it produces primarily dysphoric rather than euphoric effects, reducing abuse potential. Its dual mechanism targeting both monoamine reuptake and orexin-2 receptors makes it unique among stimulants.
Dose Information
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset |
|---|---|---|---|---|
| Oral | 30-60 min | 30-90 min | 2-4 hrs | 4-8 hrs |
Effect Profile
Scores (1–10) curated from multiple sources:
- Effect keyword matching from PsychonautWiki catalog
- Weighted by importance: core (×3), major (×2), minor (×1)
Strong euphoria and anxiety/jitters with mild focus, low stimulation
Tolerance
Tolerance Decay
Tolerance appears to build over 1–2 weeks of daily use and decays over 1–2 weeks of abstinence, consistent with other therapeutic stimulants; data quality is limited and largely extrapolated from clinical practice and user reports rather than controlled trials.
Cross-Tolerances
Effects
- Increased alertness
- Physical Euphoria
- Muscle relaxation
- Physical euphoria
- Restlessness
- Insomnia
- Dry mouth
- Increased heart rate
- Motor impairment
- Sedation
- Wakefulness
- Focus enhancement
- Motivation enhancement
- Cognitive euphoria
- Anxiety
- Dysphoria
- Dizziness
- Drowsiness
- Motor control loss
- Confusion
- Appetite suppression
- Light sensitivity
- Disinhibition
- Acuity suppression
- Decreased Libido
- Acuity Suppression
- Visual acuity suppression
- Dulled perception
- Internal Hallucination
- Perception of bodily heaviness